CRYSTAL BRYAN: Open Payments
NPI 1427887496 · ANNISTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 34 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $183 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $169 |
| AstraZeneca Pharmaceuticals LP | 4 | $82 |
| Amgen Inc. | 5 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: Wegovy, OTEZLA, GVOKE HYPOPEN, Ozempic, JARDIANCE, BREZTRI, AIRSUPRA, TRELEGY ELLIPTA.
Industry payments across AL — which companies pay providers there.
